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Chemical neuromodulation of cognitive control
avoidance
Monja I Frobo¨se1 and Roshan Cools1,2
Why do we so often fail to exert cognitive control, even though
we are in principle able to do so? In this review, we begin to
address this question by considering the contribution of the
major ascending neuromodulators that are often implicated in
cognitive control and motivation, in particular dopamine,
noradrenaline and serotonin. Accumulating evidence indicates
that cognitive control is subjectively costly and people generally
choose to refrain frommentally effortful tasks, despite, at times,
devastating consequences. This tendency to avoid cognitive
control tasks has been shown to be sensitive to
catecholaminergic interventions in rodents and humans, where
choices about cognitive control can be altered even in the
absence of performance changes. Such effects might reflect
modulation by dopamine and/or noradrenaline of a variety of
mechanisms that contribute to our motivation for cognitive
control. These likely include the calculation and integration into
behavior of both the expected value (i.e. cost vs benefit), as well
as outcome uncertainty of exerting cognitive control. In addition,
serotonin might impact cognitive control avoidance by
modulating specifically the computation of effort costs.
Advancing our understanding of the distinct roles of the various
chemical neuromodulators will help elucidate the computational
mechanisms that contribute to our tendency to avoid difficult
cognitive tasks.
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Introduction
Cognitive control is effortful, subjectively costly and
people are generally biased to avoid it [1,2,3,4].
They prefer to perform a task with less rather than more
task-switching [5] and with lower rather than higher
working memory load [6]. On average, people also choose
to forego a higher monetary reward to avoid a more
demanding task [6,7]. This can be considered paradoxi-
cal, given the following observations. First, cognitive
control is a hallmark of the human mind and the brain
region commonly associated with cognitive control, the
prefrontal cortex [8], is exquisitely well developed.
Accordingly, we are very good at exerting cognitive
control. Second, exerting cognitive control has obvious
benefits for performance, and most of us are aware that
failures of cognitive control can have disastrous conse-
quences, ranging from obesity and monetary crises to
murder. Finally, there is a growing consensus that cogni-
tive control functions, are unlikely to be metabolically
more costly than other functions, associated, for example,
with the visual cortex [9,10,11], but [12]. Therefore, a
key open question is why do we so often fail to exert
cognitive control, even though we are in principle able to
do so [13,14]. We begin to address this question by
considering the contributions to value-based choice about
cognitive control of a set of major ascending neuromo-
dulators that have been strongly implicated in motivation,
choice and cognitive control, in particular dopamine,
noradrenaline and serotonin (Figure 1a). Note that few
empirical studies have so far addressed this specific
question. Thus, we present ideas that build on current
literature, but need to be tested in future studies.
Dopamine and cognitive control avoidance
Effortful cognitive control has long been associated with
optimal catecholamine transmission. For example,
patients with disorders that implicate dopamine, like
Parkinson’s disease or attention deficit/hyperactivity dis-
order (ADHD), exhibit cognitive control deficits which
can be remedied by dopaminergic medication [15]. More-
over, dopamine is also a key ingredient in drugs that are
used to boost cognitive control in healthy adults [16].
Paradoxically, however, altering dopamine transmission
by medication or by promising reward can also impair
cognitive performance [17,18]. For example, in Parkin-
son’s disease, the dopaminergic medication doses that are
well established to improve motor control can contribute
to the development of impulse control disorder, puta-
tively by impairing cognitive control [19]. Here, we
consider the possibility that such paradoxical effects
might reflect, in part, modulation by dopamine of value-
(and effort cost) based choice about whether or not to
exert motor and cognitive control [20]. Indeed the
phasic firing of midbrain dopamine neurons are well
accepted to contribute to reward prediction error signal-
ing [21,22], which drives temporal difference learning and
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Figure 1
Synthesis and projections of major ascending neuromodulators
Illustration of (opposite) impulsivity-dependent methylphenidate effects on choice (i.e. task-switching avoidance
- left) versus task execution (i.e. switch cost and general performance - right) on the demand selection task
Hypothesized mechanism by which dopaminergic medication can improve motor, but impair cognitive control in
Parkinson’s disease
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(a) Simplified presentation of synthesis pathway and projections of the major ascending neuromodulators dopamine, noradrenaline, and serotonin.
(b) Schematic overview of the (opposite) effects of methylphenidate on the avoidance versus execution of task-switching. Methylphenidate
increased task-switching avoidance in more, relative to less impulsive participants, whereas task-switching performance was unaffected. By
contrast, methylphenidate actually enhanced performance in more impulsive participants, evidenced by speeding of responses (illustration based
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value-based choice, not only of actions that have high
value but also of valuable (while costly) cognitive tasks
[20,23].
As made explicit in the expected value of control (EVC)
model [14], one way in which dopamine might bias such
value-based learning and choice about cognitive tasks is
by altering the (expected) value of cognitive control,
which corresponds to the benefit minus the costs of
control. According to neurocomputational models of
dopamine in the basal ganglia, such as the OPAL model
and supportive empirical evidence [20, but 24], prolong-
ing (striatal) dopamine likely enhances the benefit while
also reducing the cost of actions by having opposite
effects on the D1 (GO) and D2 (NO-GO) pathways of
the basal ganglia. Thus, based on this evidence, we argue
that increases in dopamine will increase the benefits,
while reducing the costs of cognitive control. Based on
further empirical evidence for an ‘inverted U’-shaped
relationship between dopamine and reward-based versus
punishment-based learning [18,25], we also hypothesize
that excess or supraoptimal levels of dopamine might
paradoxically reduce the benefits versus the costs of
cognitive control, perhaps by acting via a presynaptic
mechanism of action, thus leading to a net reduction in
dopamine synthesis and/or release.
The nature of the control cost is currently under active
study. Some have argued that it represents an intrinsic
conflict-related cost [14,26,27], while others highlight
that it might correspond to an opportunity cost of time,
equal to either the value of the next best alternative [10]
or, following work on dopamine’s role inmotormotivation
[28,29] to an average net reward per unit time [23].
Regardless of the origin of the putatively dopaminergic
cost of cognitive control, empirical evidence for an effect
of dopamine on value-based choice about cognitive con-
trol is still scarce. So far, two studies have revealed that
challenging catecholamine transmission by amphetamine
or methylphenidate administration, which prolongs the
activity of both dopamine and noradrenaline, alters the
willingness to engage in cognitive effort. Work with
experimental animals revealed that administration of
amphetamine motivated rodent ‘slackers’ (but not
‘workers’) to choose a perceptually more demanding
option for a higher reward [30]. However, follow-up
work from the same group suggested that this effect was
mediated by changes in noradrenaline rather than dopa-
mine transmission, as selective dopamine antagonists did
not alter demand avoidance [31]. In parallel, work with
young healthy human volunteers has shown that the
administration of methylphenidate (20 mg, oral) altered
the avoidance of a classic cognitive control task, task-
switching [32], in a demand selection paradigm previ-
ously shown to be sensitive to demand avoidance [5]. The
effect of methylphenidate depended on participants’
degree of trait impulsivity, a measure that has been
associated with enhanced drug-induced dopamine release
and reduced D2/D3 (auto-)receptor availability [33–35].
More impulsive participants became more demand avoi-
dant relative to low-impulsive participants [32]. Intrigu-
ingly, in the latter study, methylphenidate did not alter
the ability to implement task-switching, as measured
during the performance of the task-switching and task-
repetition trials that followed each choice (Figure 1b),
although the drug did render performance across trial
types faster as well as more accurate, consistent with a
general performance enhancing effect. Thus in this study
methylphenidate impacted only the avoidance and not
the execution of cognitive control, with methylphenidate
actually undermining impulsive participants’ motivation
to exert control. The hypothesis that this effect reflects
modulation of the cost of cognitive effort by dopamine is
currently under study.
Which mechanism might underlie the paradoxical effects
of methylphenidate in high-impulsive individuals, where
it potentiates the avoidance of cognitive control? One
possibility, as referred to above, is that the cost of cogni-
tive control was increased, because methylphenidate
elicited supraoptimal levels of dopamine in these indi-
viduals with high trait impulsivity. Trait impulsivity has
been shown to be accompanied by enhanced baseline
levels of striatal dopamine release and low (but perhaps
more sensitive) presynaptic dopamine D2 receptor avail-
ability in the midbrain [33]. Indeed, methylphenidate has
previously been argued to act presynaptically, especially
in high dopamine states, by triggering a self-regulatory
mechanism, thus leading to a net reduction in dopamine
release [36,37].
An alternative, more speculative possibility is inspired by
opportunity cost accounts of tonic dopamine’s role in
motivating vigor (physical effort) [28,29,38]. Generaliza-
tion of this account led to the hypothesis that an increase
in tonic dopamine motivates people to avoid slow cogni-
tive control strategies because such an increase is accom-
panied by an increase in the opportunity cost of time
[10]. In one account the opportunity cost of time is
equal to the average reward rate of the environment [23].
Although one study demonstrated that dopaminergic
medication effects on physical effort-based decision
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(Figure 1 Legend Continued) on data presented in [32]). (c) Dopaminergic medication in Parkinson’s disease increases dopamine levels and
has been shown to remediate some motor symptoms, while at the same time, contributing, in a considerable proportion of patients, to impulse
(cognitive) control disorder. Increased dopamine tone has been hypothesized to elevate the cost of time due to higher average net reward per unit
time (R; [29]). This might account, in part, for the contrasting motor and cognitive effects of dopaminergic medication, which would enhance the
motivation for physical vigor, yet reduce the motivation for time costly cognitive control processes.
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making were independent of the possibility to save time
[39], another recent study provided some preliminary
supportive evidence that strategic adjustments in the
degree to which people perform fast and accurately on
Simon, task-switching and perceptual decision tasks do
indeed depend on fluctuations in the average reward rate
[40]. People with high levels of tonic dopamine might
evaluate control as relativelymore costly than people with
lower dopamine tone because their estimate of the aver-
age reward rate in the environment is increased.
One key implication of this hypothesis is that dopamine-
induced increases in an opportunity cost of time might
account, in part, for the contrasting motor and cognitive
effects of dopaminergic medication in Parkinson’s dis-
ease, described above. According to this account,
increases in tonic dopamine would be accompanied by
increases in the cost of time, which would enhance the
motivation for physical vigor [29], thus remediating bra-
dykinesia, yet reduce the motivation for time costly
cognitive control processes [23], thus potentiating
impulse control problems (Figure 1c). An account of
dopamine’s effects in terms of time costs is particularly
promising in the context of the recent observation that
dopamine neurons control the judgment of time [41].
Direct empirical evidence for a role of dopamine in
cognitive motivation comes from a separate line of work,
indicating that effects of monetary incentive reward (the
promise of a bonus) on cognitive control vary as a function
of striatal dopamine levels. This was shown to be the case
in patients with Parkinson’s disease depending on dopa-
mine cell loss [42], as well as in healthy volunteers
depending on striatal dopamine synthesis capacity, as
indexed by 6-[18F]fluoro-L-m-tyrosine (FMT) positron
emission tomography [43]. Intriguingly, in these studies,
the relationship between striatal dopamine levels and the
effect of incentives on cognitive control was negative,
such that higher striatal dopamine was associated with
more detrimental effects of reward on cognitive control
[43]. Conversely, patients with Parkinson’s disease, which
is accompanied by severe dopamine depletion in the
striatum, have been shown to exhibit paradoxically
greater beneficial effects of reward on cognitive control
than controls [17]. Although the mechanism underlying
these effects on incentivized cognitive control remains
unclear, they are certainly reminiscent of the pattern of
paradoxical effects of methylphenidate on the avoidance
of cognitive control. Indeed, changes in the value of
cognitive control might surface, in these tasks, in terms
of changes in (the effect of reward on) task performance
[44]. This concurs with the recent finding that the effect
of reward on task (-switching) performance correlated
with participants’ scores on the need for cognition scale
[45], which had been associated with the valuation of
cognitive control in earlier work [6]. In the current set of
tasks, patients with Parkinson’s disease might exhibit
greater beneficial effects of reward on cognitive control,
because there is greater cost to be offset by increases in
the benefits of cognitive control.
Noradrenaline and cognitive control
avoidance
Many drugs, including amphetamine or methylpheni-
date, prolong catecholamine transmission in a nonspecific
manner by targeting both dopamine and noradrenaline
transporters [46]. There are multiple reasons for thinking
that such drug effects on motivated cognition reflect not
just modulation by dopamine, but also noradrenaline, not
least for its well-known association with arousal and
fatigue.
For example, according to the classic adaptive gain theory
of locus coeruleus function, task engagement is modu-
lated by activity of the locus coeruleus, which favors
either exploitation (task engagement) or exploration (task
disengagement) depending on a tonic or phasic mode of
action [47]. In line with this, baseline pupil diameter at
trial onset, a measure that has been associated with locus
coeruleus activity [48], was found to correlate with lapses
of attention in a sustained attention task [49], with
participant’s tendency to explore in a gambling task
[50], with decisions to disengage from a (discrimination)
task [51] and with mental fatigue [52]. However, in
contrast to predictions of the adaptive gain theory,
prolonging tonic noradrenaline levels pharmacologically
by administering reboxetine, a selective noradrenaline
reuptake inhibitor, failed to alter task (dis)engagement or
exploratory behavior despite intervention effects on non-
specific autonomic nervous system parameters [53].
Thus, the jury is still out with regard to noradrenaline’s
role in exploration and task engagement. One way in
which the locus coeruleus-noradrenaline system might
alter task engagement and demand avoidance is by
encoding unexpected (outcome) uncertainty or surprise
due to errors in judging uncertainty [54]. For instance,
greater outcome uncertainty might elicit greater task
engagement given the greater likelihood of unsigned
(surprise) prediction error signals at outcome [55], and
thus greater potential for new learning, knowledge acqui-
sition and curiosity relief [56]. Conversely, greater cer-
tainty about the outcome of performance, whether it is
good or bad, might elicit boredom or learned helplessness
respectively, thus reducing the opportunity for new learn-
ing and task engagement. Recent empirical evidence
indicates that blocking noradrenaline, by propranolol,
increases participants’ confidence in good performance
on a dot-motion task relative to placebo [57]. It would be
interesting to contrast directly in future studies the puta-
tive role of noradrenaline in mediating a putative link
between outcome uncertainty and task engagement with
a putative role of dopamine in task engagement as a
function of the expected value of an outcome, thus the
probability (rather than uncertainty) of performing well.
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Serotonin and cognitive control avoidance
Like the catecholamines, serotonin is a major neuromo-
dulator that is strongly implicated in both motivation and
cognitive (impulse) control. Serotonin transmission is
perhaps best known for its association with (learning
about) aversive outcomes, waiting and behavioral inhibi-
tion [58,59], although there is also extensive evidence for
a complementary role in appetitive processing and reward
[60,61]. In line with the idea that serotonin also plays a
role in (the learning about time and/or effort) costs, the
optogenetic activation of serotonergic neurons in the
midbrain dorsal raphe nucleus reduced the cost of wait-
ing. Timed activation decreased premature responding in
a delayed reward task, promoting animals’ patience to
wait for a reward. Relatedly, an 8-week selective seroto-
nin reuptake inhibitor intervention (escitalopram) in
healthy humans improved decision-making about reward
and (physical) effort costs by reducing specifically effort
costs, leaving unaffected the weight of monetary incen-
tives [62]. A key question for future work is whether
such a dissociation extends from the domain of physical
effort to that of cognitive effort.
Conclusions
In this review, we highlight the potential contribution of
the major ascending neuromodulators, in particular dopa-
mine, noradrenaline and serotonin, to our tendency to
avoid cognitive control. We suggest that these chemical
neuromodulators might alter cognitive control by altering
not just the ability but also the willingness to exert
cognitive control. In line with this hypothesis, catechol-
aminergic challenges, like amphetamine and methylphe-
nidate, have been shown to alter demand avoidance while
leaving unaltered the ability to perform well on a cogni-
tive control task. Based on accumulating evidence from
chemical and functional neuroimaging studies for a role
for striatal dopamine in our motivation for cognitive
control, we hypothesize that these catecholaminergic
effects reflect in part modulation of striatal dopamine.
Striatal dopamine might alter choices about cognitive
control (avoidance) by modulating (learning about) the
expected value (i.e. cost) of cognitive task performance.
However, we also consider the role of noradrenaline in
cognitive control (avoidance), and speculate that nor-
adrenaline might contribute by modulating, instead,
our uncertainty or confidence in the outcome of perfor-
mance. Lastly, we hypothesize that serotoninmight affect
the motivation for cognitive control by modulating (time
and/or effort) costs, specifically. Overall, this review high-
lights the relevance of advancing our understanding of the
various cognitive computations carried by the different
ascending neuromodulators for elucidating the basis of
our tendency to avoid cognitive control.
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